Pharmacoeconomics of antimicrobial prophylaxis

Area of Science:

• Health Economics
• Infectious Disease Prevention
• Clinical Decision Making

Background:

• Current pharmacoeconomic analyses for infection prevention often rely on simplistic counts of cases prevented.
• Existing practices are frequently based on inadequate data regarding infection occurrence and severity.
• There is a need for more robust methods to evaluate the economic impact of infection prevention strategies.

Purpose of the Study:

• To advocate for a shift towards quantifying the benefits of infection prevention using continuous variables that account for severity.
• To highlight the utility of decision analysis in evaluating infection prevention options and their outcomes.
• To emphasize the importance of standardized methods for data collection in infection prevention.

Main Methods:

• Utilizing continuous variables (e.g., cost of antibiotics) to measure the severity and occurrence of infections.
• Applying decision analysis to model choices, probabilities of outcomes, and associated utilities in infection prevention.
• Promoting standardized methodologies for defining infection occurrence and underlying risk factors.

Main Results:

• Continuous variables provide a more comprehensive measure of benefits than simple case counts.
• Decision analysis offers a structured framework for clarifying and evaluating infection prevention strategies.
• Improved data quality through standardized methods is crucial for accurate pharmacoeconomic assessments.

Conclusions:

• Pharmacoeconomic evaluations should prioritize quantifying the severity of infection, not just the number of cases prevented.
• Decision analysis techniques are valuable tools for optimizing infection prevention strategies.
• Wider adoption of standardized methods for defining and assessing infection risk is essential for improving healthcare practices.